InventisBio Co Ltd (688382)

Currency in CNY
16.00
-1.23(-7.14%)
Closed·
688382 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
15.6917.48
52 wk Range
15.6649.68
Key Statistics
Bid/Ask
15.95 / 16.00
Prev. Close
17.23
Open
16.97
Day's Range
15.69-17.48
52 wk Range
15.66-49.68
Volume
16.37M
Average Volume (3m)
16.98M
1-Year Change
-52.8024%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
688382 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
32.55
Upside
+103.44%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 32.55
(+103.44% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Apr 29, 2026
EPS / Forecast
-- / --
Revenue / Forecast
43M / --
EPS Revisions
Last 90 days

688382 Income Statement

Compare 688382 to Peers and Sector

Metrics to compare
688382
Peers
Sector
Relationship
P/E Ratio
−32.8x−11.7x−0.4x
PEG Ratio
0.800.110.00
Price/Book
6.7x4.2x2.6x
Price / LTM Sales
139.1x10.4x3.0x
Upside (Analyst Target)
91.8%51.8%56.2%
Fair Value Upside
Unlock5.5%8.9%Unlock

InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positive/human epidermal growth factor receptor 2-breast cancer. The company also develops D—2570, which is in phase III, II, and I clinical trials, as well as preclinical trials to treat autoimmune disease; and Darbinurad (D-0120), which is in phase II clinical trial to treat gout. In addition, it is developing YF087 which is in preclinical trial to treat MSI-high solid tumors; YF550 which is in preclinical trial to treat chromosome instability solid tumors; and YF057 which is in preclinical trial to treat atopic dermatitis and asthma. InventisBio Co., Limited was founded in 2013 and is based in Shanghai, China.

Employees
182
Market
China

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
193,04M33,38%3,36B
Other Institutional Investors
229,66M39,71%4,00B
Public Companies & Retail Investors
155,65M26,91%2,71B
Total
578,35M100,00%10,06B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
InventisBio Inc.19,08%110 329 9371 919 741
HSBC Jintrust Fund Management Company Limited3,06%17 675 122307 547

FAQ

What Is the InventisBio (688382) Stock Price Today?

The InventisBio stock price today is 16,00 CNY.

What Stock Exchange Does InventisBio Trade On?

InventisBio is listed and trades on the Shanghai Stock Exchange.

What Is the Stock Symbol for InventisBio?

The stock symbol for InventisBio is "688382."

What Is the InventisBio Market Cap?

As of today, InventisBio market cap is 9,96B CNY.

What Is InventisBio's Earnings Per Share (TTM)?

The InventisBio EPS (TTM) is -0,53.

When Is the Next InventisBio Earnings Date?

InventisBio will release its next earnings report on Aug 20, 2026.

From a Technical Analysis Perspective, Is 688382 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has InventisBio Stock Split?

InventisBio has split 0 times.

How Many Employees Does InventisBio Have?

InventisBio has 182 employees.

What is the current trading status of InventisBio (688382)?

As of Jun 26, 2026, InventisBio (688382) is trading at a price of 16,00 CNY, with a previous close of 17,23 CNY. The stock has fluctuated within a day range of 15,69 CNY to 17,48 CNY, while its 52-week range spans from 15,66 CNY to 49,68 CNY.

What Is InventisBio (688382) Price Target According to Analysts?

The average 12-month price target for InventisBio is 32,55 CNY, with a high estimate of 32.55 CNY and a low estimate of 32.55 CNY. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +103,44% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.